Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Am J Transplant. 2019 Dec 27;20(4):977–987. doi: 10.1111/ajt.15739

FIGURE 3.

FIGURE 3

Tolerance induction to OVA+ and third-party (BM12) skin grafts. Diagrams and timelines for in vivo (A) OVA+ and (B) BM12 graft experiments. C, WT C57BL/6 and OBI mice treated with anti-CD45RB, on days 0, 1, 3, 5, and 7, develop long-standing tolerance to OVA+ skin grafts. μMT mice, which lack B cells, fail to develop tolerance to the skin grafts. D, WT C57BL/6 mice develop tolerance to BM12 grafts after anti-CD45RB treatment, while OBI mice fail under the same conditions. WT C57BL/6, but not OBI mice, develop tolerance to third-party BM12 skin grafts following anti-CD45RB treatment. ns, nonsignificant. *P < .05. OBI, ovalbumin (OVA)-specific BCR mice; OVA, ovalbumin; WT, wild type; μMT, B6.129S2-Ighmtm1Cgn/J